Literature DB >> 19840673

Antibody quantity versus quality after influenza vaccination.

JingQi Feng1, Upma Gulati, Xiaoju Zhang, Wendy A Keitel, David M Thompson, Judith A James, Linda F Thompson, Gillian M Air.   

Abstract

The correlates for protection against influenza infection are incompletely characterized. We have applied an ELISA strategy that distinguishes antibodies against native viral surface antigens (potentially neutralizing) from antibodies directed against internal and denatured viral proteins (not neutralizing) to three groups of vaccinated subjects: (1) participants in a study of repeated annual vaccination, (2) elderly subjects and (3) patients with Systemic Lupus Erythematosus compared to control subjects. Antibody increase after vaccination was inversely related to the level of pre-existing antibodies in all groups; most subjects had significant initial antibody levels and showed little increase in amount of antibody after vaccination, but the avidity of their serum antibodies tended to increase. Antibodies against denatured virus proteins varied with vaccine formulation; vaccines that are more recent have less total protein for the same amount of native hemagglutinin. We propose an index consisting of rank order of antibody level plus antibody avidity, both measured against native virus, plus hemagglutination-inhibition antibody titer, as a useful measure of immunity against influenza.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840673      PMCID: PMC2765411          DOI: 10.1016/j.vaccine.2009.06.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Epitopes on protein antigens: misconceptions and realities.

Authors:  W G Laver; G M Air; R G Webster; S J Smith-Gill
Journal:  Cell       Date:  1990-05-18       Impact factor: 41.582

2.  Efficacy of sequential annual vaccination with inactivated influenza virus vaccine.

Authors:  W A Keitel; T R Cate; R B Couch
Journal:  Am J Epidemiol       Date:  1988-02       Impact factor: 4.897

3.  Preparation of impermeable ghosts and inside-out vesicles from human erythrocyte membranes.

Authors:  T L Steck; J A Kant
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

4.  Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Authors:  T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

5.  Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children.

Authors:  D B Burlington; P F Wright; K L van Wyke; M A Phelan; R E Mayner; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

6.  Crystal structure of a peptide complex of anti-influenza peptide antibody Fab 26/9. Comparison of two different antibodies bound to the same peptide antigen.

Authors:  M E Churchill; E A Stura; C Pinilla; J R Appel; R A Houghten; D H Kono; R S Balderas; G G Fieser; U Schulze-Gahmen; I A Wilson
Journal:  J Mol Biol       Date:  1994-08-26       Impact factor: 5.469

7.  Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.

Authors:  Shelly Gulati; David F Smith; Gillian M Air
Journal:  Virol J       Date:  2009-02-14       Impact factor: 4.099

8.  Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin.

Authors:  J M White; I A Wilson
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

9.  Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.

Authors:  Iain Stephenson; Rose Gaines Das; John M Wood; Jacqueline M Katz
Journal:  Vaccine       Date:  2007-02-27       Impact factor: 3.641

10.  Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination.

Authors:  Upma Gulati; Wendy A Keitel; Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2007-07       Impact factor: 4.380

View more
  25 in total

1.  B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Joan T Merrill; Virginia C Roberts; Amy B Dedeke; Barbara R Neas; Linda F Thompson; Joel M Guthridge; Judith A James
Journal:  Arthritis Rheum       Date:  2011-12

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

3.  Inactivated influenza vaccines: pre-vaccination haemagglutinin-antibody titres influence the vaccine response but not necessarily the vaccine effectiveness.

Authors:  Pierre-Olivier Lang
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 4.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

5.  Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.

Authors:  Gillian M Air; Jingqi Feng; Tao Chen; Michelle L Joachims; Judith A James; Linda F Thompson
Journal:  J Clin Immunol       Date:  2011-07-06       Impact factor: 8.317

6.  Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus.

Authors:  E S Vista; S R Crowe; L F Thompson; G M Air; J M Robertson; J M Guthridge; J A James
Journal:  Lupus       Date:  2012-02       Impact factor: 2.911

7.  Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.

Authors:  Sherry R Crowe; Joan T Merrill; Evan S Vista; Amy B Dedeke; David M Thompson; Scott Stewart; Joel M Guthridge; Timothy B Niewold; Beverly S Franek; Gillian M Air; Linda F Thompson; Judith A James
Journal:  Arthritis Rheum       Date:  2011-08

8.  Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.

Authors:  Lisa C Lindesmith; Michael L Mallory; Taylor A Jones; Charles Richardson; Robert R Goodwin; Frank Baehner; Paul M Mendelman; Robert F Bargatze; Ralph S Baric
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

9.  Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.

Authors:  Morgan D McSweeney; Limei Shen; Alexander C DeWalle; Jordan B Joiner; Elizabeth C Ciociola; Dharmendra Raghuwanshi; Matthew S Macauley; Samuel K Lai
Journal:  J Control Release       Date:  2020-10-07       Impact factor: 9.776

Review 10.  Immunological assessment of influenza vaccines and immune correlates of protection.

Authors:  Adrian Reber; Jacqueline Katz
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.